Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Egermark

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
International Urogynecology Journal|October 19, 2011
Time-to-effect with darifenacin in overactive bladder: a pooled analysisVik Khullar, Jenelle Foote, Yodit Seifu, et al.
Drug, Healthcare and Patient Safety|October 12, 2012
A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trialsJan Tack, Jean-Jacques Wyndaele, Greg Ligozio, et al.
Neurourology and Urodynamics|September 23, 2010
Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrumentNorman Zinner, Kathleen Kobashi, Patricia Koochaki, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|October 4, 2008
Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 yearsBrian Olshansky, Ursula Ebinger, José Brum, et al.
Bioengineering & Translational Medicine|May 19, 2025
AI-assisted warfarin dose optimisation with CURATE.AI for clinical impact: Retrospective data analysisTiffany Rui Xuan Gan, Lester W J Tan, Mathias Egermark, et al.
European Heart Journal. Digital Health|January 24, 2024
CURATE.AI-assisted dose titration for anti-hypertensive personalized therapy: study protocol for a multi-arm, randomized, pilot feasibility trial using CURATE.AI (CURATE.AI ADAPT trial)Anh T L Truong, Shi-Bei Tan, Golda Z Wang, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
International Urogynecology Journal|October 19, 2011
Time-to-effect with darifenacin in overactive bladder: a pooled analysisVik Khullar, Jenelle Foote, Yodit Seifu, et al.
Drug, Healthcare and Patient Safety|October 12, 2012
A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trialsJan Tack, Jean-Jacques Wyndaele, Greg Ligozio, et al.
Neurourology and Urodynamics|September 23, 2010
Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrumentNorman Zinner, Kathleen Kobashi, Patricia Koochaki, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|October 4, 2008
Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 yearsBrian Olshansky, Ursula Ebinger, José Brum, et al.
Bioengineering & Translational Medicine|May 19, 2025
AI-assisted warfarin dose optimisation with CURATE.AI for clinical impact: Retrospective data analysisTiffany Rui Xuan Gan, Lester W J Tan, Mathias Egermark, et al.
European Heart Journal. Digital Health|January 24, 2024
CURATE.AI-assisted dose titration for anti-hypertensive personalized therapy: study protocol for a multi-arm, randomized, pilot feasibility trial using CURATE.AI (CURATE.AI ADAPT trial)Anh T L Truong, Shi-Bei Tan, Golda Z Wang, et al.
Pageof 1